Everything below concerns 胰高血糖素受体. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Where the concentration of the enzyme is much less than the concentration of the substrate, the rate of reaction is directly proportional to the total enzyme concentration. The hydrolysis of a peptide bond however is an energetically favourable reaction. Recent experiments with both crude caricain and purified caricain indicated that the reaction which controls detoxification of a wheat gliadin digest at pH7.5 and 37 °C was indeed a 1st order reaction with a rate constant of 1.7 x 10 −4 sec.−1. The rate of reaction was followed by the disappearance of gliadin peptides which were toxic to rat liver lysosomes.
Analytes that are totally excluded, elute with the free volume outside around the particles (Vo), the total exclusion limit, while analytes that are completely delayed, elute with the solvent, marking the total permeation volume of the column, including also the solvent held inside the pores (Vi). The total volume can be considered by the following equation, where Vg is the volume of the polymer gel and Vt is the total volume:
Four steps are followed in the standard process of plastination: fixation, dehydration, forced impregnation in a vacuum, and hardening. Water and lipid tissues are replaced by curable polymers, which include silicone, epoxy, and polyester-copolymer. The first step of plastination, fixation, frequently uses a formaldehyde-based solution, and serves two functions. Dissecting the specimen to show specific anatomical elements can be time-consuming. Formaldehyde or other preserving solutions help prevent decomposition of the tissues. They may also confer a degree of rigidity. This can be beneficial in maintaining the shape or arrangement of a specimen. A stomach might be inflated or a leg bent at the knee, for example. After any necessary dissections have taken place, the specimen is placed in a bath of acetone (freezing point −95 °C; −139 °F) at −20 to −30 °C (−4 to −22 °F). The volume of the bath should be 10 times that of the specimen. The acetone is renewed two times over the course of six weeks. The acetone draws out all the water and replaces it inside the cells. In the third step, the specimen is then placed in a bath of liquid polymer, such as silicone rubber, polyester, or epoxy resin. In a partial vacuum, the acetone is made to boil at a low temperature. As the acetone vaporizes and leaves the cells, it draws the liquid polymer in behind it, leaving a cell filled with liquid plastic. The plastic must then be cured with gas, heat, or ultraviolet light, to harden it.
The spontaneous decay of free protons has never been observed, and protons are therefore considered stable particles according to the Standard Model. However, some grand unified theories (GUTs) of particle physics predict that proton decay should take place with lifetimes between 1031 and 1036 years. The experimental lower bound for the mean lifetime is 0.96×1030 years. The mean lifetime measures decay to any product. Lifetimes for decay to specific products is also measured. For example, experiments at the Super-Kamiokande detector in Japan gave lower limits for proton mean lifetime of 1.6×1034 years for decay to an antimuon and a neutral pion, and 2.4×1034 years for decay to a positron and a neutral pion. Protons are known to transform into neutrons through the process of electron capture (also called inverse beta decay). For free protons, this process does not occur spontaneously but only when energy is supplied. The equation is:
Sources: en.wikipedia.org
=== Terpolymers === Terpolymers of PVDF are the most promising one in terms of electromechanically induced strain. The most commonly used PVDF-based terpolymers are P(VDF-TrFE-CTFE) and P(VDF-TrFE-CFE). This relaxor-based ferroelectric terpolymer is produced by random incorporation of the bulky third monomer (chlorotrifluoroethylene, CTFE) into the polymer chain of P(VDF-TrFE) copolymer (which is ferroelectric in nature). This random incorporation of CTFE in P(VDF-TrFE) copolymer disrupts the long-range ordering of the ferroelectric polar phase, resulting in the formation of nano-polar domains. When an electric field is applied, the disordered nano-polar domains change their conformation to all-trans conformation, which leads to large electrostrictive strain and a high room-temperature dielectric constant of ~50.
Katy Higginson, lately Deputy Head, Royal and Coronation Unit, Foreign, Commonwealth and Development Office. For services to British Foreign Policy, to International Development, and to the Coronation of Their Majesties The King and The Queen. Dr Andi Hoxhaj, Lecturer in Law (Assistant Professor of Law), University College London. For services to UK/Albania Relations. Professor Alan Jamieson, Director, Deep Sea Centre, University of Western Australia. For services to Marine Biology, Subsea Engineering and Exploration. Dipak Karadia, Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. Haifa Al Kaylani, President and Founder, Arab International Women's Forum. For services to women, to young people, and to cultural relations between the UK and the countries of the Middle East and North Africa region. Moses Kirkconnell III, Member of Parliament for Cayman Brac West and Little Cayman, Cayman Islands. For services to the Caymanian People, to the Tourism Industry, and to District Administration in the Cayman Islands. Gabrielle Kirstein, Founder and Chief Executive Officer, Feeding Hong Kong. For services to the community and tackling food waste and food poverty in Hong Kong. Leona Lewis, Singer-Songwriter, Performer and Philanthropist. For services to Music and to Charity. Sarah Lingard, lately Head of Events, Royal and Coronation Unit, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to the Coronation of Their Majesties The King and The Queen.
==== Yeast Two-hybrid Screens ==== Yeast two-hybrid analyses have been adapted for protease-substrate discovery. As protease exosites play roles in protein-protein recognition and interaction, biologists have used exosites as tools to screen for protease interactors and potential substrates. These protease exosite scanning assays use protease exosites as bait to scan a cDNA library for possible interacting partners. Another early adaptation of yeast two-hybrid screening in protease-substrate discovery is Inactive-catalytic-domain capture (ICDC). This approach attempts to avoid the limitation of protease exosite scanning, which fails to account for any substrates that do not require exosites to for recognition before cleavage. The bait for these assays are immobilized catalytically inactive mutant protease domains that cannot cleave and release their substrates once bound. While useful in early degradomic studies, the limitations of adapted yeast two-hybrid screens have forced the field to move on to higher-throughput approaches for protease-substrate discovery. Their high rate of false positives and negatives, inability to recognize complex interactions, lack of biologically compartmentalization, and failure to account for post-translational modifications necessary for protein-protein interactions hamper their usefulness. Thus they have been largely replaced by proteomic methods as technology has improved.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.